Shots:
- Novo Nordisk will acquire Akero Therapeutics, incl. its lead asset efruxifermin (EFX), to expand its metabolic dysfunction-associated steatohepatitis (MASH) portfolio
- As per the deal, Novo Nordisk will acquire Akero for $54/share in an all-cash transaction totaling ~$4.7B, along with one non-tradeable CVR of $6/share (~$0.5B) tied to EFX’s US FDA approval for compensated cirrhosis due to MASH, representing the total deal value of ~$5.2B
- EFX (SC; QW) is being evaluated in P-III (SYNCHRONY) programme, which incl. 3 trials aimed at supporting regulatory approval for treating pre-cirrhotic (F2-F3) MASH & compensated cirrhosis (F4) due to MASH
Ref: Novo Nordisk | Image: Akero Therapeutics | Press Release
Related News:- Halozyme Therapeutics to Acquire Elektrofi for ~$900M, Expanding its Drug Delivery Offerings
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
